Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
http://www.immunetolerance.org/
International clinical research consortium dedicated to the clinical evaluation of novel tolerogenic approaches for the treatment of autoimmune diseases, asthma and allergic diseases, and the prevention of graft rejection. They aim to advance the clinical application of immune tolerance by performing high quality clinical trials of emerging therapeutics integrated with mechanism-based research. In particular, they aim to: * Establish new tolerance therapeutics * Develop a better understanding of the mechanisms of immune function and disease pathogenesis * Identify new biomarkers of tolerance and disease Their goals are to identify and develop treatment game changers for tolerance modulating therapies for the treatment of immune mediated diseases and disabling conditions, and to conduct high quality, innovative clinical trials and mechanistic studies not likely to be funded by other sources or to be conducted by private industry that advance our understanding of immunological disorders. In the Immune Tolerance Network's (ITN) unique hybrid academic/industry model, the areas of academia, government and industry are integral to planning and conducting clinical studies. They develop and fund clinical trials and mechanistic studies in partnership. Their development model is a unique, interactive process. It capitalizes on their wide-ranging, multidisciplinary expertise provided by an advisory board of highly respected faculty from institutions worldwide. This model gives investigators special insight into developing high quality research studies. The ITN is comprised of leading scientific and medical faculty from more than 50 institutions in nine countries worldwide and employs over 80 full-time staff at the University of California San Francisco (UCSF), Bethesda, Maryland and Benaroya Research Institute in Seattle, Washington.
Proper citation: Immune Tolerance Network (ITN) (RRID:SCR_001535) Copy
Network of clinical centers and a data coordinating center established to conduct studies of islet transplantation in patients with type 1 diabetes.
Proper citation: Clinical Islet Transplantation Consortium (CITC) (RRID:SCR_014385) Copy
https://www.qut.edu.au/research/research-projects/landmark-biobanks
A repository of human tissue samples collected during the LANDMark study (Longitudinal Assessment of Neuropathy in Diabetes using novel ophthalmic markers). The LANDMark Biobank longitudinal dataset contains blood and tissue (skin) samples and matching detailed phenotypic data of three microvascluar complications of type 1 diabetes: neuropathy, nephropathy and retinopathy.
Proper citation: LANDMark BioBanks (RRID:SCR_014534) Copy
https://sites.google.com/ucsd.edu/drc/home
Research center across five institutions for clinical research in diabetes. Collaborators include UC San Diego's School of Medicine, Salk Institute, Cedars-Sinai Medical Center, UC Los Angeles' School of Medicine, and LA Biomedical Research Center.
Proper citation: University of California San Diego - University of California Los Angeles Diabetes Research Center (RRID:SCR_015100) Copy
Research center for translational research on type 2 diabetes with a strong emphasis on translation into real world health care settings and communities.
Proper citation: Georgia Center for Diabetes Translation Research (RRID:SCR_015185) Copy
Research center which operates in collaboration with the University of Alabama Birmingham Comprehensive Diabetes Center to promote excellence in diabetes research and patient care. The DRC supports the areas of animal physiology, human biology and intervention and translational research. It focuses on developing new methods to treat, prevent, and ultimately cure diabetes and its complications.
Proper citation: University of Alabama at Birmingham Diabetes Research Center (RRID:SCR_015107) Copy
https://diabetes.med.umich.edu/partners/michigan-diabetes-research-center-mdrc
Multidisciplinary unit of the University of Michigan funded by the National Institute of Diabetes and Digestive and Kidney Diseases/National Institute of Health. Promotes new discoveries and enhance scientific progress through the support of basic and clinical research related to diabetes, its complications, and related disorders. Creates environment that supports innovative research; attracts and retains early stage investigators and investigators new to diabetes research; provides core services that leverage funding and unique expertise; fosters interdisciplinary collaborations; raises awareness and interest in fundamental and clinical diabetes research at their institutions, as well as locally, regionally, and nationally.
Proper citation: Michigan Diabetes Research Center (RRID:SCR_015112) Copy
Consortium of laboratory-based and clinical investigators who research etiology, pathogenesis, treatment and cure of type 1 and type 2 diabetes, and their associated microvascular and atherosclerotic complications.
Proper citation: Boston Area Diabetes Endocrinology Research Center (RRID:SCR_015072) Copy
http://www.einstein.yu.edu/centers/diabetes-research/
Research center that facilitates the research of diabetes and related studies in obesity, metabolism and endocrinology
Proper citation: Einstein-Mount Sinai Diabetes Research Center (RRID:SCR_015070) Copy
https://www.niddk.nih.gov/research-funding/research-programs/hematology-centers
Online portal with thorough information about hematology research centers and cores. Each entry details the center's research aims, its activities and core services, and links to pilot programs.
Proper citation: Hematology Centers (RRID:SCR_015321) Copy
Research center for diabetes that offers regional and national resources to investigators for translation interventions into healthcare settings, communities, and populations at-risk. The CDTR supports studies investigating the root causes of diabetes and disparities as well as the prevention of obesity as a major contributing cause of Type 2 diabetes.
Proper citation: Washington University Center for Diabetes Translation Research (RRID:SCR_015204) Copy
http://chicagodiabetesresearch.org
Center to improve the lives of people with diabetes and people at risk for diabetes through prevention, improved diabetes care, and community empowerment.
Proper citation: Chicago Center for Diabetes Translation Research (RRID:SCR_015179) Copy
http://www.einstein.yu.edu/centers/diabetes-translational-research/
Center designed to increase collaboration and enhance communication among diabetes researchers from multiple institutions and diverse disciplines
Proper citation: New York Regional Center for Diabetes Translation Research (RRID:SCR_015174) Copy
University-affiliated center that promotes research in diabetes and related metabolic and endocrine disorders at Yale University.
Proper citation: Yale Diabetes Research Center (RRID:SCR_015142) Copy
https://labnodes.vanderbilt.edu/drtc
University-affiliated center that facilitates the discovery, application, and translation of scientific knowledge to improve the lives of people with diabetes.
Proper citation: Vanderbilt Diabetes Research and Training Center (RRID:SCR_015153) Copy
http://depts.washington.edu/diabetes/
University-affiliated center to support both basic and clinical research in diabetes and related metabolic disorders with the ultimate purpose of translating findings into opportunities to prevent these diseases and to improve clinical care and outcomes.
Proper citation: University of Washington Diabetes Research Center (RRID:SCR_015126) Copy
http://www.hopkinsmedicine.org/diabetes-research-center/
Center whose goal is to understand the causes of both type 1 and 2 diabetes and promotes translational research that is aimed at reducing the burden of these diseases in the U.S. It has a specific focus on childhood diabetes and diabetes that affects minority populations.
Proper citation: Johns Hopkins University - University of Maryland Diabetes Research Center (RRID:SCR_015086) Copy
Network of centers to conduct studies of islet transplantation in patients with type 1 diabetes to improve the safety and long-term success of methods for transplanting islets. It is the aim of this trial to improve methods of isolating islets, to improve techniques for the administering those transplanted islets; and to develop approaches to minimize the toxic effects of immunosuppressive drugs required for transplantation.
Proper citation: Clinical Islet Transplantation Study (RRID:SCR_001515) Copy
http://www.t1diabetes.nih.gov/T1D-PTP/
THIS RESOURCE IS NO LONGER IN SERVICE, documented August 22, 2016. Investigator access is provided to the established facilities and expertise needed to extend, enhance and validate preclinical studies of promising new therapeutics in cases where additional preclinical testing is needed to validate potential therapies under disease-specific conditions and in multiple animal models before therapeutics can enter the Type 1 Diabetes Rapid Access to Intervention Development (T1D-RAID) development pipeline. The T1D-RAID program provides resources for pre-clinical development of drugs, natural products, and biologics that will be tested as new therapeutics in type 1 diabetes clinical trials. The T1D-RAID program is not currently accepting applications. The T1D-PTP program currently supports two contracts, which are separate from each other and from the T1D-RAID NCI contract resources, to assist in preclinical development of therapeutics for T1D: * Agents to be tested for Preclinical Efficacy in Prevention or Reversal of Type 1 Diabetes in Rodent Models. Type 1 Diabetes Preclinical Testing Program (T1D-PTP) (NOT-DK-09-006) * Needs for Preclinical Efficacy Testing of Promising Agents to Prevent or Reverse Diabetic Complications (NOT-DK-09-009) The T1D-RAID and T1D-PTP are programs intended to remove the most common barriers to progress in identification and development of new therapies for Type 1 Diabetes. The common goal of these programs is to support and provide for the preclinical work necessary to obtain proof of principle establishing that a new molecule or novel approach will be a viable candidate for expanded clinical evaluation.
Proper citation: Type 1 Diabetes Preclinical Testing Program (RRID:SCR_006861) Copy
http://diabetes.niddk.nih.gov/dm/pubs/control/index.aspx
Clinical study that showed that keeping blood glucose levels as close to normal as possible slows the onset and progression of eye, kidney, and nerve diseases caused by diabetes. EDIC is a follow-up study of people who participated in DCCT. The DCCT involved 1,441 volunteers, ages 13 to 39, with type 1 diabetes and 29 medical centers in the United States and Canada. Volunteers had to have had diabetes for at least 1 year but no longer than 15 years. They also were required to have no, or only early signs of, diabetic eye disease. The study compared the effects of standard control of blood glucose versus intensive control on the complications of diabetes. Intensive control meant keeping hemoglobin A1C levels as close as possible to the normal value of 6 percent or less. The A1C blood test reflects a person''''s average blood glucose over the last 2 to 3 months. Volunteers were randomly assigned to each treatment group. DCCT Study Findings * Intensive blood glucose control reduces risk of ** eye disease: 76% reduced risk ** kidney disease: 50% reduced risk ** nerve disease: 60% reduced risk When the DCCT ended, researchers continued to study more than 90 percent of participants. The follow-up study, called Epidemiology of Diabetes Interventions and Complications (EDIC), is assessing the incidence and predictors of cardiovascular disease events such as heart attack, stroke, or needed heart surgery, as well as diabetic complications related to the eye, kidney, and nerves. The EDIC study is also examining the impact of intensive control versus standard control on quality of life. Another objective is to look at the cost-effectiveness of intensive control. EDIC Study Findings * Intensive blood glucose control reduces risk of ** any cardiovascular disease event: 42% reduced risk ** nonfatal heart attack, stroke, or death from cardiovascular causes: 57% reduced risk
Proper citation: Diabetes Control and Complications Trial (RRID:SCR_006805) Copy
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
You can save any searches you perform for quick access to later from here.
We recognized your search term and included synonyms and inferred terms along side your term to help get the data you are looking for.
If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the sources that were queried against in your search that you can investigate further.
Here are the categories present within RRID that you can filter your data on
Here are the subcategories present within this category that you can filter your data on
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
